Kinnevik AB Class A
74.00
SEK
+4.00
(+5.71%)
Kinnevik AB Class A
STO:KINV_A
(Nasdaq Stockholm)
Recent
price
74.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.- Similar Companies
- Business
- Kinnevik AB (STO:KINV-A) is a Sweden-based investment company that serves as an active owner and operational partner to technology-enabled growth companies across healthcare, software, climate tech, and marketplaces sectors. Founded in 1936 and headquartered in Stockholm with an additional office in London, the firm invests from early-stage to growth-phase, providing patient capital and dedicated support to a concentrated portfolio of over 20 larger companies, including core holdings such as Cityblock (value-based healthcare), Mews (hospitality software), Pleo (spend management), Spring Health (mental health solutions), and TravelPerk (business travel platform); healthcare investments like Recursion (techbio drug discovery), Enveda (biotech drug discovery), Strand Therapeutics (programmable mRNA therapies), Pelago (substance use management), and Transcarent (healthcare access); software platforms including Cedar (patient payments), Omnipresent (global hiring), Wordsmith AI (legal AI), and Encube (manufacturing AI); climate tech ventures such as Aira (residential heating electrification), Stegra (green steel), Solugen (sustainable chemicals), Agreena (regenerative agriculture), and Charm Industrial (carbon removal); and marketplaces like Oda/Mathem (Nordic online grocery), Instabee (e-commerce logistics), Job&Talent (essential work matching), Omio (travel booking), and Vivino (wine marketplace). Kinnevik operates geographically across Europe and the United States, with portfolio companies delivering services in over 80 countries and targeting innovative entrepreneurs reshaping industries for consumers, employers, health plans, and urban populations. In recent developments, the company fully divested its stake in Tele2 to iliad/NJJ for SEK 13 billion and executed an extraordinary cash distribution of SEK 23 per share (SEK 6.4 billion total) in June 2024; concentrated its portfolio toward core assets, which grew revenues over 55% on average with profitability gains; led Strand Therapeutics' USD 153 million Series B with a USD 35 million investment and participated in Aira's EUR 150 million round with EUR 35 million in September 2025; invested EUR 30 million leading Tandem Health's EUR 40 million round in June 2025; followed TravelPerk's USD 200 million raise and Yokoy acquisition, Recursion's Exscientia buyout, and Enveda's USD 130 million funding and first drug clinic entry in 2024; and outlined five-year expectations at its October 2024 Capital Markets Day while electing new board members in December 2024.
Company News
Kinnevik AB (KNEVF) Q3 2026 Earnings Call Transcript
Kinnevik AB (KNEVF) Q2 2026 Earnings Call Transcript
Kinnevik AB (KNEVF) Q1 2026 Earnings Call Transcript
Kinnevik AB (KNVKF) Q4 2025 Earnings Call Transcript
Kinnevik AB (KNVKF) Q3 2025 Earnings Call Transcript
Kinnevik AB (KNVKF) Q2 2025 Earnings Call Transcript
Kinnevik AB (KNVKF) Q1 2025 Earnings Call Transcript
Kinnevik AB (KNVKF) Q4 2024 Earnings Call Transcript
Kinnevik: Limited Downside, Strong Upside Potential
Kinnevik AB (KNVKF) Q3 2024 Earnings Call Transcript
Kinnevik: Attractive Valuation, But Capital Allocation Will Be Key